Clinical trial

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

NCT00181558

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Atrasentan Normalized identity: atrasentanView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Zoledronic Acid (Zometa) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2001-12-01

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Adenocarcinoma of the Prostateverified · MONDO: prostate adenocarcinoma

Interventions

AtrasentanDRUG · verified · RxNorm: atrasentan

Zoledronic Acid (Zometa)DRUG

Sponsors & collaborators

Massachusetts General Hospitallead sponsor

Dana-Farber Cancer Institutecollaborator

Brigham and Women's Hospitalcollaborator

Abbottcollaborator

Mapped research locations

BostonMassachusetts, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00181558 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.